NASDAQ: PRPH
- Last Close 4.35
- Sector Healthcare
- Industry Diagnostics & Research
- Investment Style Small Blend
- Day Range 4.35 – 4.37
- Year Range 4.05 – 12.69
- Market Cap 73.2759 Mil
- Volume / Avg 12,146.0 / 43,774.5
- Price / Sales 0.97
- Price / Book 1.24
- Forward Div Yield —
- Trailing Div Yield 6.90%
Morningstar‘s Stock Analysis PRPH
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile PRPH
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
ProPhase Labs Inc
XNAS: PRPH
| Bactolac Pharmaceutical Inc
GREY: BTCA
| Inotiv Inc
XNAS: NOTV
| Rafarma Pharmaceuticals Inc
PINX: RAFA
| |
Price
| 4.35 | — | 3.06 | 0.18 |
Currency
| USD | USD | USD | USD |
Change
| $0.00 (0.00%) | — | +$0.05 (1.66%) | $0.00 (2.64%) |
Market Cap
| 73.28 Mil | — | 78.90 Mil | 14.70 Mil |
Industry
| Diagnostics & Research | Packaged Foods | Diagnostics & Research | Drug Manufacturers - Specialty & Generic |
Sector
|
Healthcare
|
Consumer Defensive
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for ProPhase Labs Inc Stock
No. PRPH does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
PRPH’s market cap is 73.28 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
PRPH’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
PRPH’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare PRPH’s historical performance against its industry peers and the overall market.